Copyright © 2019. Inderes Oy. All rights reserved.

Faron Pharmaceuticals

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Tiedotteet
25.2.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Notice of Full-Year Results and Annual Report

Company announcement, 25 February 2021 at 7.00 am GMT / 9.00 am EET

TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company, will publish its audited full-year results for the twelve months ended 31 December 2020 on Thursday 25 March 2021 at 7:00 GMT / 9:00 EET. The Annual Report 2020, including audited financial statements for the full year, will be published on the same day.

Tiedotteet
17.2.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Holding(s) in the Company

Company announcement, 17 February 2021 at 3.40pm GMT / 5.40pm EET

TURKU - FINLAND - Faron Pharmaceuticals Oy (First North: FARON, AIM: FARN), the clinical stage biopharmaceutical company, has on 16 February 2021 received notifications from Mr. Timo Syrjälä and Mr. Tom-Erik Lind of the decrease of their holdings due to issuance of new shares. 

Trading in the Placing Shares commenced on First North and AIM on 16 February 2021.

Tiedotteet
12.2.
2021

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, SINGAPORE, HONG KONG OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Tiedotteet
12.2.
2021

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, SINGAPORE, HONG KONG OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Tiedotteet
11.2.
2021

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, SINGAPORE, HONG KONG OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Tiedotteet
26.1.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")
  • U.S. Food and Drug Administration (FDA) approval of new HIBISCUS study protocol in patients with COVID-19 infection
  • Company seeking patent protection for the sequential use of IV interferon beta-1a and corticosteroids
  • Pipeline expansion into additional organ protection indications
  • CMC scale-up in progress

Company announcement, 26 January 2021 at 9.00 AM (EET)
Inside information

Tiedotteet
20.1.
2021
  • Cholangiocarcinoma becomes fifth tumour cohort to show early signs of efficacy
  • Increased bexmarilimab dosing schedule and high baseline regulatory T cell count associated with clinical benefit
  • High levels of soluble Clever-1 observed in MATINS patients
  • Soluble Clever-1 has the capacity to suppress T cell activation
  • Increased bexmarilimab dosing frequency to counter high levels of soluble Clever-1 underway

 

Company announcement, 20 January 2021 at 9.00 AM PM (EEST)

Insider information
 

Tiedotteet
18.1.
2021
  • The DoD grants $6.1 million for the HIBISCUS study
  • Faron and the US Air Force to explore Traumakine's wider potential to prevent multi-organ failure after ischemia and reperfusion

Company announcement, 18 January 2021 at 9.00 AM (EET)
Inside information
 

Tiedotteet
4.1.
2021

TURKU - FINLAND, January 4, 2021 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, today announced that Dr. Markku Jalkanen, Chief Executive Officer of Faron Pharmaceuticals, will present in a pre-recorded presentation at the virtual H.C. Wainwright BioConnect Conference that will be available on-demand starting Monday, January 11, 2021 at 6:00 a.m. ET.

An audio webcast of the presentations will be available in the "Investors" section on Faron's website at https://www.faron.com/investors

Tiedotteet
21.12.
2020

Company announcement, 21 December 2020 at 9.00 am (EET)

TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces the following dates for the Company's financial reporting in 2021:

25 March    Financial statement release for the full year 2020 and Annual Report 2020 including financial statements for the full year

26 August   Half-year financial report for the period 1 January to 30 June 2021

Faron Pharmaceuticals

Faron Pharmaceuticals

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the endothelial receptors involved in regulation of immune response, in oncology and organ damage.

Our pipeline consists of two drug candidates and development programmes Clevegen (FP-1305) and Traumakine (FP-1201-lyo). Clevegen aims to tackle several cancer types by activating immunity; Traumakine organ trauma and vascular damage by stopping vascular leakage. Both programmes have advanced to first-in-human clinical trials following promising pre-clinical data. 

Faron is based in Turku, Finland. Further information is available at www.faron.com.